Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Summary

This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase III clinical trial. It is designed to evaluate the efficacy and safety of SHEN26 capsules in Chinese adult patients with mild to moderate COVID-19

Timeline

Start

2023-05-13

Primary completion

2024-05

Completion

2024-07

Drugs

Indications